Next, we observed a three- to five-fold greater expression of BCL2 mRNA in NCB progenitors compared to early and advanced stage CML progenitors (Figure 3B), a finding that may underlie the relative senstivity of NCB progenitors to ABT-199. Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.